The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Sionna Therapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC each reported beneficial ownership of 2,639,418 shares of Sionna Therapeutics common stock.
  • Percent of class: The reported holdings represent 5.8% of Sionna Therapeutics' outstanding common stock.
  • Shared voting power: Both reporting persons reported shared voting power over 2,639,412 shares and sole voting power of 0 shares.
  • Shared dispositive power: Both reporting persons reported shared dispositive power over 2,639,418 shares and sole dispositive power of 0 shares.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Signing date: The statement was signed on October 8, 2026, by Ameen Soetan as attorney-in-fact for both reporting entities.

Goldman Sachs Discloses Passive Stake in Sionna Therapeutics as of September 30, 2026

According to the filing, The Goldman Sachs Group, Inc. (incorporated in Delaware) and Goldman Sachs & Co. LLC (organized in New York) jointly filed a Schedule 13G disclosing their beneficial ownership of common stock, $0.001 par value per share, in Sionna Therapeutics, Inc. (CUSIP 829401108). Sionna Therapeutics is headquartered at 21 Hickory Drive, Suite 500, Waltham, Massachusetts 02451, according to the filing. The filing identifies The Goldman Sachs Group, Inc. as a parent holding company and control person (type HC, CO), and Goldman Sachs & Co. LLC as a broker-dealer, investment adviser, and other entity (type BD, OO, IA).

The filing discloses that both entities beneficially own an aggregate of 2,639,418 shares, representing 5.8% of the class, with shared voting power covering 2,639,412 shares and shared dispositive power covering 2,639,418 shares. Neither entity reported any sole voting or sole dispositive power. As disclosed in Exhibit 99.2, Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc. and is the entity that directly owns or may be deemed to beneficially own the securities as a registered broker-dealer and registered investment adviser.

Exhibit 99.3 states that the filing "reflects the securities beneficially owned by certain operating units (collectively, the 'Goldman Sachs Reporting Units') of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates." The same exhibit notes that the Goldman Sachs Reporting Units disclaim beneficial ownership of securities held in certain client accounts and certain investment entities to the extent interests are held by persons other than the Goldman Sachs Reporting Units. The certifications in the filing state that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly disclosed a 5.8% beneficial ownership position of 2,639,418 shares in Sionna Therapeutics, Inc. common stock via a Schedule 13G, with the triggering event dated September 30, 2026, and the statement signed October 8, 2026.